[HTML][HTML] Recent progress in treatment of hepatocellular carcinoma
Z Chen, H **e, M Hu, T Huang, Y Hu… - American journal of …, 2020 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …
worldwide. In the past decade, there have been improvements in non-drug therapies and …
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
M Omata, AL Cheng, N Kokudo, M Kudo, JM Lee… - Hepatology …, 2017 - Springer
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the
sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient …
sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
Hepatocellular carcinoma: a review
J Balogh, D Victor III, EH Asham… - Journal of …, 2016 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a
leading cause of cancer-related death worldwide. In the United States, HCC is the ninth …
leading cause of cancer-related death worldwide. In the United States, HCC is the ninth …
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update
N Wen, Y Cai, F Li, H Ye, W Tang, P Song… - Bioscience …, 2022 - jstage.jst.go.jp
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …
leading cause of cancer-related mortality worldwide. This review is an updated version that …
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial
Background & Aims Transarterial chemoembolization with doxorubicin-eluting beads (DC
Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B …
Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B …
EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma
European Association For The Study Of … - Journal of …, 2012 - journal-of-hepatology.eu
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …
Treatment of liver cancer
CY Liu, KF Chen, PJ Chen - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …
Treatment of intermediate-stage hepatocellular carcinoma
Hepatocellular carcinoma (HCC)—closely associated with liver cirrhosis and, in fact, the
main cause of death in patients with such disease—is now recognized as one of the most …
main cause of death in patients with such disease—is now recognized as one of the most …